

Algorae Pharmaceuticals Limited

ABN: 14 104 028 042
ASX: 1AI
OTCQB: LVCLY

28 December 2023

Section 708A Cleansing Statement - Amended

This notice is given by Algorae Pharmaceuticals Limited (Company) under Section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act).

The Company hereby confirms that:

- a) the Company has issued on 28 December 2023:
 - i. 25,000,000 fully paid ordinary shares upon conversion of Performance Rights B.
- b) the shares were issued without disclosure to investors under Part 6D.2 of the Corporations, Act;
- c) As a disclosing entity the company is subject to regular reporting and disclosure obligations;
- d) As at the date of this notice the Company has complied with:
 - i. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - ii. section 674 of the Corporations Act as it applies to the Company; and
- e) as at the date of this notice, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

Yours Sincerely,



Madhukar Bhalla

Company Secretary

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| |
|-------------------------------------------------------|
| Name of entity ALGORAE PHARMACEUTICALS LIMITED |
| ABN 14 104 028 042 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|--------------------------|
| Name of Director | David Richard Hainsworth |
| Date of last notice | 10 November 2023 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Direct or indirect interest | Indirect and Direct |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | UNION SQUARE CAPITAL PTY LTD <ENDEAVOR A/C> Director & Controlling Shareholder |
| Date of change | 28 December 2023 |
| No. of securities held prior to change | Indirectly 5,625,000 ordinary shares 312,500 unlisted options Directly 10,000,000 Ordinary Shares 10,000,000 Performance Rights B 10,000,000 Performance Rights C 10,000,000 Performance Rights D |
| Class | As above |
| Number acquired | Directly 10,000,000 ordinary shares |
| Number disposed | Directly 10,000,000 Performance Rights B |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small> | =Nil= |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| No. of securities held after change | Indirect 5,625,000 Ordinary Shares 312,500 unlisted options Directly 20,000,000 Ordinary Shares 10,000,000 Performance Rights C 10,000,000 Performance Rights D |
| Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | Performance Rights B Converted to shares |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Detail of contract | N/A |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small> | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small> | |
| Interest after change | |

Part 3 – +Closed period

| | |
|----------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No. |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | |
| If prior written clearance was provided, on what date was this provided? | |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| |
|-------------------------------------------------------|
| Name of entity ALGORAE PHARMACEUTICALS LIMITED |
| ABN 14 104 028 042 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|--------------------------|
| Name of Director | MR BRADLEY ROLAND LATHAM |
| Date of last notice | 10 November 2023 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| Direct or indirect interest | Direct |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | |
| Date of change | 28 December 2023 |
| No. of securities held prior to change | 15,000,000 Ordinary Shares 5,000,000 Performance Rights B 5,000,000 Performance Rights C 5,000,000 Performance Rights D |
| Class | Ordinary Shares |
| Number acquired | 5,000,000 Ordinary Shares |
| Number disposed | 5,000,000 Performance Rights B |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small> | Nil |
| No. of securities held after change | 20,000,000 Ordinary Shares 5,000,000 Performance Rights C 5,000,000 Performance Rights D |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|
| Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | Performance Rights B Converted to shares |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Detail of contract | N/A |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small> | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small> | |
| Interest after change | |

Part 3 – +Closed period

| | |
|----------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No. |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | |
| If prior written clearance was provided, on what date was this provided? | |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|-----------------------|----------------------------------------|
| Name of entity | ALGORAE PHARMACEUTICALS LMITIED |
| ABN | 14 104 028 042 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|---------------------|
| Name of Director | Bradley John Dilkes |
| Date of last notice | 10 November 2023 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Direct or indirect interest | Indirect and direct |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | CIPATER PTY LTD - Director & Controlling Shareholder CICHLI PTY LTD - Director & Controlling Shareholder |
| Date of change | 28 December 2023 |
| No. of securities held prior to change | Indirect CIPATER PTY LTD – 27,150,000 Ordinary Shares CICHLI PTY LTD – 5,000,000 Ordinary Shares Directly 10,000,000 Ordinary Shares 10,000,000 Performance Rights B 10,000,000 Performance Rights C 10,000,000 Performance Rights D |
| Class | As above |
| Number acquired | Held Directly 10,000,000 Ordinary Shares |
| Number disposed | 10,000,000 Performance Rights B |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small> | =Nil= |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| No. of securities held after change | Indirect CIPATER PTY LTD – 27,150,000 Ordinary Shares CICHLI PTY LTD – 5,000,000 Ordinary Shares Directly 20,000,000 Ordinary Shares 10,000,000 Performance Rights C 10,000,000 Performance Rights D |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Performance Rights B Converted to shares. |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Detail of contract | N/A |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | |
| Interest after change | |

Part 3 – +Closed period

| | |
|----------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No. |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | |
| If prior written clearance was provided, on what date was this provided? | |

+ See chapter 19 for defined terms.